Pharmacological Activation of Peroxisome Proliferator-Activated Receptor {Delta} Increases Sphingomyelin Synthase Activity in THP-1 Macrophage-Derived Foam Cell

Peroxisome proliferator-activated receptors in cardiac energy metabolism and cardiovascular disease

(2016) Thekkuttuparambil Ananthanarayanan Ajith et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Fragmented Lactic Acid Bacterial Cells Activate Peroxisome Proliferator-Activated Receptors and Ameliorate Dyslipidemia in Obese Mice

(2016) Futoshi Nakamura et al.   JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY

A selective peroxisome proliferator-activated receptor δ agonist PYPEP suppresses atherosclerosis in association with improvement of the serum lipoprotein profiles in human apolipoprotein B100 and cholesteryl ester transfer protein double transgenic mice

(2016) Noriyuki Naya et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Discovery, synthesis and biological evaluation of 2-(4-(N-phenethylsulfamoyl)phenoxy)acetamides (SAPAs) as novel sphingomyelin synthase 1 inhibitors

(2015) Ya-li Li et al.   BIOORGANIC & MEDICINAL CHEMISTRY

The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges

(2015) Wai San Cheang et al.   BRITISH JOURNAL OF PHARMACOLOGY

Hematopoietic knockdown of PPARδ reduces atherosclerosis in LDLR−/− mice

(2015) G Li et al.   GENE THERAPY

Chronic peroxisome proliferator-activated receptorβ/δ agonist GW0742 prevents hypertension, vascular inflammatory and oxidative status, and endothelial dysfunction in diet-induced obesity

(2015) Marta Toral et al.   JOURNAL OF HYPERTENSION

Peroxisome Proliferator–Activated Receptor δ Agonist GW1516 Attenuates Diet-Induced Aortic Inflammation, Insulin Resistance, and Atherosclerosis in Low-Density Lipoprotein Receptor Knockout Mice

(2013) Lazar A. Bojic et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia

(2011) Yun-Jung Choi et al.   ATHEROSCLEROSIS

Sphingomyelin synthase overexpression increases cholesterol accumulation and decreases cholesterol secretion in liver cells

(2011) Nianlong Yan et al.   Lipids in Health and Disease

Sphingomyelin Synthase 2 Is One of the Determinants for Plasma and Liver Sphingomyelin Levels in Mice

(2009) Jing Liu et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Both the Peroxisome Proliferator-Activated Receptor δ Agonist, GW0742, and Ezetimibe Promote Reverse Cholesterol Transport in Mice by Reducing Intestinal Reabsorption of HDL-Derived Cholesterol

(2009) François Briand et al.   CTS-Clinical and Translational Science

Sphingomyelin Synthase 2 Deficiency Attenuates NFκB Activation

(2008) Tiruneh K. Hailemariam et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

PPAR -mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis

(2008) Y. Takata et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA